Literature DB >> 18309313

Hormones of the gut-brain axis as targets for the treatment of upper gastrointestinal disorders.

Gareth J Sanger1, Kevin Lee.   

Abstract

The concept of the gut forming the centre of an integrated gut-brain-energy axis - modulating appetite, metabolism and digestion - opens up new paradigms for drugs that can tackle multiple symptoms in complex upper gastrointestinal disorders. These include eating disorders, nausea and vomiting, gastroesophageal reflux disease, gastroparesis, dyspepsia and irritable bowel syndrome. The hormones that modulate gastric motility represent targets for gastric prokinetic drugs, and peptides that modify eating behaviours may be targeted to develop drugs that reduce nausea, a currently poorly treated condition. The gut-brain axis may therefore provide a range of therapeutic opportunities that deliver a more holistic treatment of upper gastrointestinal disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18309313     DOI: 10.1038/nrd2444

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  34 in total

1.  Metoclopramide in the treatment of diabetic gastroparesis.

Authors:  Allen Lee; Braden Kuo
Journal:  Expert Rev Endocrinol Metab       Date:  2010

2.  Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders.

Authors:  Gareth J Sanger; Lin Chang; Chas Bountra; Lesley A Houghton
Journal:  Therap Adv Gastroenterol       Date:  2010-09       Impact factor: 4.409

Review 3.  Gastroparesis and functional dyspepsia: excerpts from the AGA/ANMS meeting.

Authors:  H P Parkman; M Camilleri; G Farrugia; R W McCallum; A E Bharucha; E A Mayer; J F Tack; R Spiller; M Horowitz; A I Vinik; J J Galligan; P J Pasricha; B Kuo; L A Szarka; L Marciani; K Jones; C R Parrish; P Sandroni; T Abell; T Ordog; W Hasler; K L Koch; K Sanders; N J Norton; F Hamilton
Journal:  Neurogastroenterol Motil       Date:  2009-12-09       Impact factor: 3.598

4.  Devices for the treatment of obesity: will understanding the physiology of satiety unravel new targets for intervention?

Authors:  Ram Weiss
Journal:  J Diabetes Sci Technol       Date:  2008-05

5.  Shark genomes provide insights into elasmobranch evolution and the origin of vertebrates.

Authors:  Yuichiro Hara; Kazuaki Yamaguchi; Koh Onimaru; Mitsutaka Kadota; Mitsumasa Koyanagi; Sean D Keeley; Kaori Tatsumi; Kaori Tanaka; Fumio Motone; Yuka Kageyama; Ryo Nozu; Noritaka Adachi; Osamu Nishimura; Reiko Nakagawa; Chiharu Tanegashima; Itsuki Kiyatake; Rui Matsumoto; Kiyomi Murakumo; Kiyonori Nishida; Akihisa Terakita; Shigeru Kuratani; Keiichi Sato; Susumu Hyodo; Shigehiro Kuraku
Journal:  Nat Ecol Evol       Date:  2018-10-08       Impact factor: 15.460

6.  Dietary Polysaccharides in the Amelioration of Gut Microbiome Dysbiosis and Metabolic Diseases.

Authors:  Shokouh Ahmadi; Rabina Mainali; Ravinder Nagpal; Mahmoud Sheikh-Zeinoddin; Sabihe Soleimanian-Zad; Shaohua Wang; Gagan Deep; Santosh Kumar Mishra; Hariom Yadav
Journal:  Obes Control Ther       Date:  2017-12-18

Review 7.  Agile delivery of protein therapeutics to CNS.

Authors:  Xiang Yi; Devika S Manickam; Anna Brynskikh; Alexander V Kabanov
Journal:  J Control Release       Date:  2014-06-21       Impact factor: 9.776

8.  Loss of enteroendocrine cells in mice alters lipid absorption and glucose homeostasis and impairs postnatal survival.

Authors:  Georg Mellitzer; Anthony Beucher; Viviane Lobstein; Pascal Michel; Sylvie Robine; Michèle Kedinger; Gérard Gradwohl
Journal:  J Clin Invest       Date:  2010-04-01       Impact factor: 14.808

Review 9.  Irritable bowel syndrome: a microbiome-gut-brain axis disorder?

Authors:  Paul J Kennedy; John F Cryan; Timothy G Dinan; Gerard Clarke
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

10.  Ghrelin and functional dyspepsia.

Authors:  Takashi Akamizu; Hiroshi Iwakura; Hiroyuki Ariyasu; Kenji Kangawa
Journal:  Int J Pept       Date:  2010-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.